Patents by Inventor Lance Steward
Lance Steward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230190636Abstract: Methods for delivery of a biologic agent to the dermis or superficial muscles by topical application of the agent are provided. The methods comprise, in one embodiment, treating or conditioning a skin area to disrupt the stratum corneum in the skin area to define a treated skin area and applying a formulation comprising a biologic agent to the treated skin area.Type: ApplicationFiled: July 14, 2022Publication date: June 22, 2023Inventors: Lance Steward, Amy Brideau-Andersen, Jie Shen, Lydia Andrews-Jones, Hsiang Ho, Betsy Bloom, Guang Wei Lu, Fangjing Wang, Sunny Kumar, Gregory Nicholson, Ron Broide
-
Patent number: 11248219Abstract: Single chain polypeptide fusion protein, comprising: a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety; a protease cleavage site; a translocation domain; a first spacer located between the non-cytotoxic protease and the protease cleavage site; and a second spacer located between the galanin targeting moiety and the translocation domain.Type: GrantFiled: May 20, 2019Date of Patent: February 15, 2022Assignees: Ipsen Bioinnovation Limited, Allergan, Inc.Inventors: Peter James, Keith Foster, John Chaddock, Roger Aoki, Lance Steward, Joseph Francis
-
Publication number: 20210275691Abstract: An in vivo assay to evaluate topical delivery of a biologic agent from a formulation is provided. The assay comprises treating a skin area of a CD hairless rat with tape stripping to disrupt the stratum corneum in the skin area to define a treated skin area and topically applying a formulation to the treated skin area. The formulation, in one embodiment, comprises the biologic agent and a pharmaceutically acceptable carrier. Delivery of the biologic agent into the skin from the topically applied formulation is evaluated via in vitro or in vivo techniques.Type: ApplicationFiled: May 30, 2019Publication date: September 9, 2021Inventors: Jie Shen, Hsiang Ho, Lydia Andrew-Jones, Betsy Bloom, Greg Nicholson, Lance Steward, Amy Brideau-Anderson, Terrence Hunt, Ron Broide, David Rupp, David Canty
-
Patent number: 10619146Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, ?-endorphin, bradykinin, substance P, dynorphin and/or nociceptin.Type: GrantFiled: September 7, 2016Date of Patent: April 14, 2020Assignees: Ipsen Bioinnovation Limited, Allergan Inc.Inventors: Keith Foster, John Chaddock, Charles Penn, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Publication number: 20190343759Abstract: Methods for delivery of a biologic agent to the dermis or superficial muscles by topical application of the agent are provided. The methods comprise, in one embodiment, treating or conditioning a skin area to disrupt the stratum corneum in the skin area to define a treated skin area and applying a formulation comprising a biologic agent to the treated skin area.Type: ApplicationFiled: May 10, 2019Publication date: November 14, 2019Inventors: Lance Steward, Amy Brideau-Andersen, Jie Shen, Lydia Andrews-Jones, Hsiang Ho, Betsy Bloom, Guang Wei Lu, Fangjing Wang, Sunny Kumar, Gregory Nicholson, Ron Broide
-
Publication number: 20190309277Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which protease is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent (eg clostridial neurotoxin L-chain or IgA protease); a galanin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent (eg GALR1, GALR2, or GALR3 receptor); a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease and the galanin Targeting Moiety; a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent (eg HN domain of clostridial neurotoxin); a first spacer located between the non-cytotoxic protease and the proteType: ApplicationFiled: May 20, 2019Publication date: October 10, 2019Applicants: IPSEN BIOINNOVATION LIMITED, ALLERGAN, INC.Inventors: Peter JAMES, Keith FOSTER, John CHADDOCK, Roger AOKI, Lance STEWARD
-
Publication number: 20170327810Abstract: A single chain polypeptide fusion protein, comprising: a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety; a protease cleavage site at which site the fusion protein is cleavable by a protease; a translocation domain capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; a first spacer located between the non-cytotoxic protease and the protease cleavage site; and a second spacer located between the galanin targeting moiety and the translocation domain.Type: ApplicationFiled: July 27, 2017Publication date: November 16, 2017Inventors: Peter JAMES, Keith FOSTER, John CHADDOCK, Roger Kei AOKI, Lance STEWARD, Joseph FRANCIS
-
Publication number: 20160369257Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, ?-endorphin, bradykinin, substance P, dynorphin and/or nociceptin.Type: ApplicationFiled: September 7, 2016Publication date: December 22, 2016Applicants: Ipsen Bioinnovation Ltd., Allergan Inc.Inventors: Keith FOSTER, John CHADDOCK, Charles PENN, Kei Roger AOKI, Joseph FRANCIS, Lance STEWARD
-
Patent number: 9474807Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, ?-endorphin, bradykinin, substance P, dynorphin and/or nociceptin.Type: GrantFiled: June 10, 2014Date of Patent: October 25, 2016Assignees: IPSEN BIOINNOVATION LIMITED, ALLERGAN INC.Inventors: Keith Foster, John Chaddock, Charles Penn, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Patent number: 9243301Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, which is located between the non-cytotoxic protease and the Targeting Moiety; and a translocation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; wherein the Targeting Moiety is BAM, ?-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. Nucleic acid sequences encoding the fusion proteins, methods of preparing same and uses thereof are also described.Type: GrantFiled: March 13, 2012Date of Patent: January 26, 2016Assignees: Allergan, Inc., Ipsen Bioinnovation LimitedInventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Patent number: 9139635Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.Type: GrantFiled: March 28, 2011Date of Patent: September 22, 2015Assignees: SYNTAXIN, LTD., ALLERGAN, INC.Inventors: Keith Foster, John Chaddock, Charles Penn, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Publication number: 20150197739Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which protease is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease and the galanin Targeting Moiety; a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; a first spacer located between the non-cytotoxic protease and the protease cleavage site, wherein said first spacer comprises an amino acid sequence of from 4 to 25 amino acid residues; and a second spType: ApplicationFiled: August 27, 2013Publication date: July 16, 2015Inventors: Peter James, Keith Foster, John Chaddock, Roger Kei Aoki, Lance Steward, Joseph Francis
-
Patent number: 9072736Abstract: Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.Type: GrantFiled: January 27, 2012Date of Patent: July 7, 2015Assignees: Allergan, Inc., Syntaxin LimitedInventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, K. Roger Aoki, Joseph Francis, Lance Steward
-
Patent number: 9012195Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.Type: GrantFiled: July 17, 2013Date of Patent: April 21, 2015Assignees: Syntaxin, Ltd., Allergan, Inc.Inventors: Keith Foster, John Chaddock, Charles Penn, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Patent number: 8940870Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.Type: GrantFiled: February 22, 2013Date of Patent: January 27, 2015Assignees: Syntaxin, Ltd., Allergan, Inc.Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Publication number: 20140294797Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, ?-endorphin, bradykinin, substance P, dynorphin and/or nociceptin.Type: ApplicationFiled: June 10, 2014Publication date: October 2, 2014Inventors: Keith FOSTER, John CHADDOCK, Charles PENN, Kei Roger AOKI, Joseph FRANCIS, Lance STEWARD
-
Patent number: 8778634Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, ?-endorphin, bradykinin, substance P, dynorphin and/or nociceptin.Type: GrantFiled: March 13, 2012Date of Patent: July 15, 2014Assignees: Syntaxin, Ltd., Allergan, Inc.Inventors: Keith Foster, John Chaddock, Charles Penn, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Publication number: 20140056870Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which cleaves a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin Targeting Moiety that binds a Binding Site on the nociceptive sensory afferent, which can undergo endocytosis to be incorporated into an endosome; a protease cleavage site where the fusion protein is cleavable by a protease located between the non-cytotoxic protease and the galanin Targeting Moiety; a translocation domain that translocates the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; a first spacer from 4 to 25 amino acids between the non-cytotoxic protease and protease cleavage site; and a second spacer comprising from 4 to 35 residues between the galanin Targeting Moiety and translocation domain. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.Type: ApplicationFiled: August 27, 2012Publication date: February 27, 2014Applicants: ALLERGAN, INC., SYNTAXIN LIMITEDInventors: Peter James, Keith Foster, John Chaddock, Kei Roger Aoki, Lance Steward, Joseph Francis
-
Patent number: 8603779Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a galanin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are is also described.Type: GrantFiled: January 5, 2012Date of Patent: December 10, 2013Assignees: Syntaxin, Ltd., Allergan, Inc.Inventors: Keith Foster, John Chaddock, Charles Penn, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Publication number: 20130295643Abstract: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.Type: ApplicationFiled: July 17, 2013Publication date: November 7, 2013Inventors: Keith FOSTER, John CHADDOCK, Charles PENN, Kei Roger AOKI, Joseph FRANCIS, Lance STEWARD